Method for use of IGF-binding protein for selective sensitization of target cells in vivo

• US 20030035788A1
• Filed: 09/18/2001
• Published: 02/20/2003
• Est. Priority Date: 09/19/2000
• Status: Abandoned Application

• Current Assignee: Insmed Incorporated
• Original Assignee: Insmed Incorporated
• Inventors: Mascarenhas, Desmond
• Application Number:
  US09/956,508
• Publication Number:
  US 20030035788A1
• Time in Patent Office: Days
• US Class Current: 424/85.1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 31/513 having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• CPC Class Codes: A61K 31/704 attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin digitoxin A61K31/7048
• CPC Class Codes: A61K 38/30 Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 insulin-like growth factor binding protein A61K38/1754
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

New methods for the treatment of human disease are provided. IGFBP-3 is administered together with a co-administered agent to subjects having disease, thereby alleviating the symptoms of the disease, under conditions where administration of IGFBP-3 alone at the maximum practicable dose has no measurable beneficial effect on the disease condition.

Claims

1. A method for alleviating the symptoms of cancer, comprising administering a co-administered agent or treatment regimen together with an effective amount of insulin-like growth factor binding protein-3 (IGFBP-3) or derivative thereof to a subject having cancer under conditions wherein the administration of IGFBP-3 or derivative alone does not alleviate said symptoms of cancer.

2. The method of claim 1 wherein said co-administered agent is a chemical agent selected from the group consisting of alkylating agents, antimetabolites, Vinca alkaloids, podophyllotoxins, antitumor antibiotics, nitrosoureas, metallic DNA modifying compounds and microtubule stabilizers.

3. The method of claim 1 wherein said co-administered agent is a biological agent selected from the group consisting of nutrient limitation, antibodies, vaccines, peptides, cytokines, receptor ligands and nucleic acids.

4. The method of claim 1 wherein said co-administered agent is a physical agent selected from the group consisting of heat, pressure, osmolarity, acidity and radiation.

5. The method of claim 2, wherein the cancer is selected from the group consisting of breast, prostate, colon, ovarian, pancreatic, gastric and lung cancer.

6. The method of claim 5, wherein the co-administered agent is a chemical agent selected from the group consisting of doxorubicin, paclitaxel, methotrexate, tamoxifen, cyclophosphamide, vincristine, etoposide, streptozotocin and 5-fluorouracil.

7. The method of claim 6, wherein said cancer is breast cancer.

8. The method of claim 6, wherein said cancer is prostate cancer.

9. The method of claim 6, wherein said cancer is colon cancer.

10. The method of claim 6, wherein said cancer is lung cancer.

11. The method of claim 6 wherein said co-administered agent is paclitaxel.

12. The method of claim 6, wherein said co-administered agent is 5-fluorouracil.

13. The method of claim 6, wherein said co-administered agent is doxorubicin.

14. The method of claim 7 wherein said co-administered agent is paclitaxel.

15. The method of claim 7, wherein said co-administered agent is 5-fluorouracil.

16. The method of claim 7, wherein said co-administered agent is doxorubicin.

17. The method of claim 8 wherein said co-administered agent is paclitaxel.

18. The method of claim 8, wherein said co-administered agent is 5-fluorouracil.

19. The method of claim 8, wherein said co-administered agent is doxorubicin.

20. The method of claim 1, wherein said IGFBP-3 is administered at about 0.01 to about 50 milligrams per kilogram total body weight per day (mg/kg/day).

21. A kit for use in the treatment of cancer, comprising:

at least one container comprising IGFBP, and

instructions for administration of IGFBP and a co-administered agent or treatment regimen for the treatment of cancer.

22. The kit of claim 21, further comprising at least one container comprising a co-administered chemical agent.